BR102012009317B1 - Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo - Google Patents

Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo Download PDF

Info

Publication number
BR102012009317B1
BR102012009317B1 BR102012009317-0A BR102012009317A BR102012009317B1 BR 102012009317 B1 BR102012009317 B1 BR 102012009317B1 BR 102012009317 A BR102012009317 A BR 102012009317A BR 102012009317 B1 BR102012009317 B1 BR 102012009317B1
Authority
BR
Brazil
Prior art keywords
flow
cyclodextrins
preparation
drug
inclusion
Prior art date
Application number
BR102012009317-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR102012009317A2 (pt
Inventor
Joel José Passos
Robson Augusto Souza Dos Santos
Rubén Dario Sinisterra Millán
Original Assignee
Universidade Federal De Minas Gerais - Ufmg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De Minas Gerais - Ufmg filed Critical Universidade Federal De Minas Gerais - Ufmg
Priority to BR102012009317-0A priority Critical patent/BR102012009317B1/pt
Priority to PCT/BR2013/000135 priority patent/WO2013155586A1/fr
Publication of BR102012009317A2 publication Critical patent/BR102012009317A2/pt
Publication of BR102012009317B1 publication Critical patent/BR102012009317B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR102012009317-0A 2012-04-20 2012-04-20 Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo BR102012009317B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR102012009317-0A BR102012009317B1 (pt) 2012-04-20 2012-04-20 Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
PCT/BR2013/000135 WO2013155586A1 (fr) 2012-04-20 2013-04-22 Procédé de préparation de composés d'inclusion faisant intervenir des cyclodextrines et des substances pharmaceutiques, au moyen d'un système à flux continu

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102012009317-0A BR102012009317B1 (pt) 2012-04-20 2012-04-20 Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo

Publications (2)

Publication Number Publication Date
BR102012009317A2 BR102012009317A2 (pt) 2013-11-26
BR102012009317B1 true BR102012009317B1 (pt) 2022-05-31

Family

ID=49382731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102012009317-0A BR102012009317B1 (pt) 2012-04-20 2012-04-20 Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo

Country Status (2)

Country Link
BR (1) BR102012009317B1 (fr)
WO (1) WO2013155586A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104445325B (zh) * 2014-12-05 2016-06-01 福州大学 一种从含钾、铝矿石中提取氢氧化铝的方法
CN112190498B (zh) * 2020-10-31 2022-03-25 华南理工大学 一种具有水溶性的茶碱和环糊精包合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
BRPI0509592A (pt) * 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
JP2008508332A (ja) * 2004-08-02 2008-03-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ピロキシカム：ベータシクロデキストリン包接化合物の製造方法

Also Published As

Publication number Publication date
BR102012009317A2 (pt) 2013-11-26
WO2013155586A1 (fr) 2013-10-24

Similar Documents

Publication Publication Date Title
Khuntawee et al. Molecular dynamics simulations of the interaction of beta cyclodextrin with a lipid bilayer
JS et al. Inclusion complex system; a novel technique to improve the solubility and bioavailability of poorly soluble drugs: A review
Indulkar et al. Exploiting the phenomenon of liquid–liquid phase separation for enhanced and sustained membrane transport of a poorly water-soluble drug
JP2019059740A (ja) 高度分岐α−Ｄ−グルカン
Koch et al. Cannabidiol aqueous solubility enhancement: Comparison of three amorphous formulations strategies using different type of polymers
Cortesi et al. Dextran cross-linked gelatin microspheres as a drug delivery system
KR101834940B1 (ko) 나노입자 제조방법
CN102066399A (zh) 形成非免疫原性疏水蛋白纳米颗粒的方法及其用途
JP2008542342A5 (fr)
Ueda et al. Equilibrium state at supersaturated drug concentration achieved by hydroxypropyl methylcellulose acetate succinate: Molecular characterization using 1H NMR technique
Singh et al. Recent advances in nanosponges as drug delivery system: a review
Zou et al. Experimental and simulation study of the solvent effects on the intrinsic properties of spherical lignin nanoparticles
Gharibzahedi et al. Nanocapsule formation by cyclodextrins
Sharma et al. Solid dispersions: A technology for improving bioavailability
CN105050585A (zh) 稳定的葡萄糖激酶活化剂组合物
Ding et al. Characterisation of spray dried microencapsules with amorphous lutein nanoparticles: Enhancement of processability, dissolution rate, and storage stability
Šalamúnová et al. Evaluation of β-glucan particles as dual-function carriers for poorly soluble drugs
Costa et al. Optimization of supercritical CO2-assisted atomization: phase behavior and design of experiments
De Melo et al. In silico and in vitro study of epiisopiloturine/hydroxypropyl-β-cyclodextrin inclusion complexes obtained by different methods
Topuz Rapid sublingual delivery of piroxicam from electrospun cyclodextrin inclusion complex nanofibers
BR102012009317B1 (pt) Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
CN106924213A (zh) 莱菔素微囊剂及其制备方法
BRPI0409741B1 (pt) método para a preparação de complexos moleculares
Feng et al. Starch-lipid and starch-protein complexes and their application
de Vargas et al. Strategies used for to improve aqueous solubility of simvastatin: a systematic review

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.